{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:23:43Z","timestamp":1715387023175},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,9]]},"DOI":"10.7759\/cureus.60005","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:20:56Z","timestamp":1715314856000},"source":"Crossref","is-referenced-by-count":0,"title":["Retinal Blood Vessel Formation in the Macula Following Intravitreal Ranibizumab Injection for Aggressive Retinopathy of Prematurity"],"prefix":"10.7759","author":[{"given":"Hiroshi","family":"Kubota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andira Bulan","family":"Nandinanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohji","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.11.001","article-title":"Retinal vasculature development in health and disease","volume":"63","author":"Selvam S","year":"2018","unstructured":"Selvam S, Kumar T, Fruttiger M. Retinal vasculature development in health and disease. Prog Retin Eye Res. 2018, 63:1-19. 10.1016\/j.preteyeres.2017.11.001","journal-title":"Prog Retin Eye Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity","volume":"382","author":"Hellstrom A","year":"2013","unstructured":"Hellstrom A, Smith LE, Dammann O. Retinopathy of prematurity. Lancet. 2013, 382:1445-57. 10.1016\/S0140-6736(13)60178-6","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology","volume":"124","author":"VanderVeen DK","year":"2017","unstructured":"VanderVeen DK, Melia M, Yang MB, Hutchinson AK, Wilson LB, Lambert SR. Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology. Ophthalmology. 2017, 124:619-33. 10.1016\/j.ophtha.2016.12.025","journal-title":"Ophthalmology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl A","year":"2019","unstructured":"Stahl A, Lepore D, Fielder A, et al.. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019, 394:1551-59. 10.1016\/S0140-6736(19)31344-3","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.06.022","article-title":"Widefield OCT-angiography and fluorescein angiography assessments of nonperfusion in diabetic retinopathy and edema treated with anti-vascular endothelial growth factor","volume":"126","author":"Couturier A","year":"2019","unstructured":"Couturier A, Rey PA, Erginay A, et al.. Widefield OCT-angiography and fluorescein angiography assessments of nonperfusion in diabetic retinopathy and edema treated with anti-vascular endothelial growth factor. Ophthalmology. 2019, 126:1685-94. 10.1016\/j.ophtha.2019.06.022","journal-title":"Ophthalmology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity, third edition","volume":"128","author":"Chiang MF","year":"2021","unstructured":"Chiang MF, Quinn GE, Fielder AR, et al.. International classification of retinopathy of prematurity, third edition. Ophthalmology. 2021, 128:51-68. 10.1016\/j.ophtha.2021.05.031","journal-title":"Ophthalmology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0b013e318285238e","article-title":"Delayed recurrent neovascularization and persistent avascular retina following intravitreal bevacizumab for retinopathy of prematurity","volume":"7","author":"Mehta S","year":"2013","unstructured":"Mehta S, Hubbard GB 3rd. Delayed recurrent neovascularization and persistent avascular retina following intravitreal bevacizumab for retinopathy of prematurity. Retin Cases Brief Rep. 2013, 7:206-9. 10.1097\/ICB.0b013e318285238e","journal-title":"Retin Cases Brief Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2019.01.12","article-title":"Fluorescein angiography of retinal vascular involution after intravitreal injection of ranibizumab for retinopathy of prematurity","volume":"12","author":"Cheng Y","year":"2019","unstructured":"Cheng Y, Liu TG, Li WY, Zhao MW, Liang JH. Fluorescein angiography of retinal vascular involution after intravitreal injection of ranibizumab for retinopathy of prematurity. Int J Ophthalmol. 2019, 12:79-82. 10.18240\/ijo.2019.01.12","journal-title":"Int J Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100281","article-title":"Persistent vascular anomalies in retinopathy of prematurity children: ultrawide-field fluorescein angiography findings until school age","volume":"3","author":"Ling XC","year":"2023","unstructured":"Ling XC, Kang EY, Huang JL, et al.. Persistent vascular anomalies in retinopathy of prematurity children: ultrawide-field fluorescein angiography findings until school age. Ophthalmol Sci. 2023, 3:100281. 10.1016\/j.xops.2023.100281","journal-title":"Ophthalmol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(21)00195-4","article-title":"2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial","volume":"5","author":"Marlow N","year":"2021","unstructured":"Marlow N, Stahl A, Lepore D, et al.. 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial. Lancet Child Adolesc Health. 2021, 5:698-707. 10.1016\/S2352-4642(21)00195-4","journal-title":"Lancet Child Adolesc Health"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.08.005","article-title":"Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings","volume":"125","author":"Lepore D","year":"2018","unstructured":"Lepore D, Quinn GE, Molle F, et al.. Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology. 2018, 125:218-26. 10.1016\/j.ophtha.2017.08.005","journal-title":"Ophthalmology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4103\/tjo.tjo_101_18","article-title":"Foveal hypoplasia and optical coherence tomographic imaging","volume":"8","author":"Kondo H","year":"2018","unstructured":"Kondo H. Foveal hypoplasia and optical coherence tomographic imaging. Taiwan J Ophthalmol. 2018, 8:181-8. 10.4103\/tjo.tjo_101_18","journal-title":"Taiwan J Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2022.05.019","article-title":"Low- and very low-dose bevacizumab for retinopathy of prematurity: reactivations, additional treatments, and 12-month outcomes","volume":"129","author":"Freedman SF","year":"2022","unstructured":"Freedman SF, Hercinovic A, Wallace DK, et al.. Low- and very low-dose bevacizumab for retinopathy of prematurity: reactivations, additional treatments, and 12-month outcomes. Ophthalmology. 2022, 129:1120-8. 10.1016\/j.ophtha.2022.05.019","journal-title":"Ophthalmology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.62.3.2","article-title":"Tear fluid angiogenic factors: potential noninvasive biomarkers for retinopathy of prematurity screening in preterm infants","volume":"62","author":"Vinekar A","year":"2021","unstructured":"Vinekar A, Nair AP, Sinha S, et al.. Tear fluid angiogenic factors: potential noninvasive biomarkers for retinopathy of prematurity screening in preterm infants. Invest Ophthalmol Vis Sci. 2021, 62:2. 10.1167\/iovs.62.3.2","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.01.028","article-title":"Structural grading of foveal hypoplasia using spectral-domain optical coherence tomography a predictor of visual acuity?","volume":"118","author":"Thomas MG","year":"2011","unstructured":"Thomas MG, Kumar A, Mohammad S, et al.. Structural grading of foveal hypoplasia using spectral-domain optical coherence tomography a predictor of visual acuity?. Ophthalmology. 2011, 118:1653-60. 10.1016\/j.ophtha.2011.01.028","journal-title":"Ophthalmology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2022.02.010","article-title":"Genotypic and phenotypic spectrum of foveal hypoplasia: a multicenter study","volume":"129","author":"Kuht HJ","year":"2022","unstructured":"Kuht HJ, Maconachie GDE, Han J, et al.. Genotypic and phenotypic spectrum of foveal hypoplasia: a multicenter study. Ophthalmology. 2022, 129:708-18. 10.1016\/j.ophtha.2022.02.010","journal-title":"Ophthalmology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.0150","article-title":"Congenital retinal macrovessel and the association of retinal venous malformations with venous malformations of the brain","volume":"136","author":"Pichi F","year":"2018","unstructured":"Pichi F, Freund KB, Ciardella A, et al.. Congenital retinal macrovessel and the association of retinal venous malformations with venous malformations of the brain. JAMA Ophthalmol. 2018, 136:372-9. 10.1001\/jamaophthalmol.2018.0150","journal-title":"JAMA Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.107.512442","article-title":"Plasma levels of vascular endothelial growth factor after treatment for cerebral arteriovenous malformations","volume":"39","author":"Kim GH","year":"2008","unstructured":"Kim GH, Hahn DK, Kellner CP, et al.. Plasma levels of vascular endothelial growth factor after treatment for cerebral arteriovenous malformations. Stroke. 2008, 39:2274-9. 10.1161\/STROKEAHA.107.512442","journal-title":"Stroke"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-022-00402-3","article-title":"Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography","volume":"8","author":"Al Rasheed R","year":"2022","unstructured":"Al Rasheed R, Adhi MI, Alowedi SA, Albdah B, Aldebasi T, Hazzazi MA. Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography. Int J Retina Vitreous. 2022, 8:53. 10.1186\/s40942-022-00402-3","journal-title":"Int J Retina Vitreous"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/213239-retinal-blood-vessel-formation-in-the-macula-following-intravitreal-ranibizumab-injection-for-aggressive-retinopathy-of-prematurity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:20:59Z","timestamp":1715314859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/213239-retinal-blood-vessel-formation-in-the-macula-following-intravitreal-ranibizumab-injection-for-aggressive-retinopathy-of-prematurity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.60005","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,9]]}}}